JP2004500553A - 前立腺ガンのマーカータンパク質 - Google Patents
前立腺ガンのマーカータンパク質 Download PDFInfo
- Publication number
- JP2004500553A JP2004500553A JP2001528702A JP2001528702A JP2004500553A JP 2004500553 A JP2004500553 A JP 2004500553A JP 2001528702 A JP2001528702 A JP 2001528702A JP 2001528702 A JP2001528702 A JP 2001528702A JP 2004500553 A JP2004500553 A JP 2004500553A
- Authority
- JP
- Japan
- Prior art keywords
- marker
- sample
- prostate cancer
- patient
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 144
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 144
- 108090000623 proteins and genes Proteins 0.000 title description 66
- 102000004169 proteins and genes Human genes 0.000 title description 63
- 239000000439 tumor marker Substances 0.000 title 1
- 239000003550 marker Substances 0.000 claims abstract description 233
- 238000000034 method Methods 0.000 claims abstract description 86
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 40
- 238000003745 diagnosis Methods 0.000 claims abstract description 30
- 239000000758 substrate Substances 0.000 claims description 85
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 70
- 239000003463 adsorbent Substances 0.000 claims description 67
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 64
- 238000012360 testing method Methods 0.000 claims description 64
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 52
- 239000002594 sorbent Substances 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 238000001514 detection method Methods 0.000 claims description 30
- 238000009739 binding Methods 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 19
- 230000017854 proteolysis Effects 0.000 claims description 19
- 238000005406 washing Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000001616 ion spectroscopy Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 238000010183 spectrum analysis Methods 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000002390 hyperplastic effect Effects 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 204
- 102100038358 Prostate-specific antigen Human genes 0.000 description 47
- 210000000582 semen Anatomy 0.000 description 44
- 150000002500 ions Chemical class 0.000 description 42
- 239000000243 solution Substances 0.000 description 39
- 239000012071 phase Substances 0.000 description 31
- 150000001413 amino acids Chemical group 0.000 description 30
- 239000007789 gas Substances 0.000 description 28
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 238000003018 immunoassay Methods 0.000 description 18
- 239000013610 patient sample Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 229910052751 metal Inorganic materials 0.000 description 13
- 239000002184 metal Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 125000001165 hydrophobic group Chemical group 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 229910021645 metal ion Inorganic materials 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000013060 biological fluid Substances 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000003795 desorption Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 102000012479 Serine Proteases Human genes 0.000 description 6
- 108010022999 Serine Proteases Proteins 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000037230 mobility Effects 0.000 description 5
- 229910052759 nickel Inorganic materials 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 125000000542 sulfonic acid group Chemical group 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- -1 sulfate anions Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000011810 insulating material Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical class NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 241000582786 Monoplex Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- WISCONQAEAWCKO-UHFFFAOYSA-N cyclohexa-2,4-diene-1-carboxylic acid Chemical compound OC(=O)C1CC=CC=C1 WISCONQAEAWCKO-UHFFFAOYSA-N 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- MVBJSQCJPSRKSW-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]prop-2-enamide Chemical compound OCC(CO)(CO)NC(=O)C=C MVBJSQCJPSRKSW-UHFFFAOYSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910021426 porous silicon Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000005659 seminal clot liquefaction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229910001258 titanium gold Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15842299P | 1999-10-07 | 1999-10-07 | |
| PCT/US2000/027682 WO2001025791A2 (en) | 1999-10-07 | 2000-10-06 | Prostate cancer marker proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500553A true JP2004500553A (ja) | 2004-01-08 |
| JP2004500553A5 JP2004500553A5 (enExample) | 2005-12-15 |
Family
ID=22568045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001528702A Pending JP2004500553A (ja) | 1999-10-07 | 2000-10-06 | 前立腺ガンのマーカータンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1224466B1 (enExample) |
| JP (1) | JP2004500553A (enExample) |
| AT (1) | ATE350662T1 (enExample) |
| AU (1) | AU7868300A (enExample) |
| CA (1) | CA2386669A1 (enExample) |
| DE (1) | DE60032784T2 (enExample) |
| WO (1) | WO2001025791A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006038674A (ja) * | 2004-07-28 | 2006-02-09 | Kazuaki Kakehi | 糖たん白質糖鎖の分析方法及び非標識糖鎖の製造方法 |
| JP2008537112A (ja) * | 2005-04-07 | 2008-09-11 | モザイクヴェス ディアグノシュティクス アンド テラポイティクス アクチェン ゲゼルシャフト | 前立腺がんの診断のためのポリペプチドマーカー |
| JP2009530624A (ja) * | 2006-03-24 | 2009-08-27 | フェノメノーム ディスカバリーズ インク | 前立腺癌を診断するために有用なバイオマーカー及びその方法 |
| JP2013528379A (ja) * | 2010-05-21 | 2013-07-11 | オームクス コーポレーション | Ｐｓａ酵素活性アッセイによる癌の検出 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1426536A (zh) * | 2000-03-20 | 2003-06-25 | 东弗吉尼亚医学院 | 前列腺癌标记 |
| AUPQ886100A0 (en) * | 2000-07-19 | 2000-08-10 | Biotron Limited | Diagnostic test |
| GB2379737A (en) * | 2001-09-05 | 2003-03-19 | Univ Geneve | Diagnostic method for spongiform encephalopathy disease |
| CA2477035A1 (en) * | 2002-02-21 | 2003-09-04 | Eastern Virginia Medical School | Protein biomarkers that distinguish prostate cancer from non-malignant cells |
| EP2211181A1 (en) | 2002-10-30 | 2010-07-28 | Proteome Sciences Plc | Diagnostic method for transmissible spongiform encephalopathies |
| ATE502300T1 (de) | 2002-12-26 | 2011-04-15 | Nitto Boseki Co Ltd | Immunoassay-verfahren |
| CA2526878A1 (en) | 2003-04-08 | 2004-10-21 | Colotech A/S | A method for detection of colorectal cancer in human samples |
| US7425700B2 (en) | 2003-05-22 | 2008-09-16 | Stults John T | Systems and methods for discovery and analysis of markers |
| GB0617429D0 (en) | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
| EP2012127A3 (en) * | 2007-07-03 | 2009-03-11 | Koninklijke Philips Electronics N.V. | Diagnostic markers for detecting prostate cancer |
| US20140134658A1 (en) * | 2010-05-21 | 2014-05-15 | Notrhwestern University, An Illinois Not For Profit Corporation | Psa enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness |
| JP6047150B2 (ja) | 2011-05-13 | 2016-12-21 | キングス・カレッジ・ロンドン | 血小板感受性に関係する方法と組成物 |
| WO2015042493A2 (en) * | 2013-09-20 | 2015-03-26 | Ohmx Corporation | Psa enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness |
| CA3146525A1 (en) | 2019-08-05 | 2021-02-11 | William Manning | Systems and methods for sample preparation, data generation, and protein corona analysis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
| US5807978A (en) * | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| CA2284137A1 (en) * | 1997-03-11 | 1998-09-17 | Sloan Kettering Institute For Cancer Research | Prostate specific antigen substrates |
| US6207370B1 (en) * | 1997-09-02 | 2001-03-27 | Sequenom, Inc. | Diagnostics based on mass spectrometric detection of translated target polypeptides |
| US6300088B1 (en) * | 1997-11-24 | 2001-10-09 | Duke University | Method of detecting prostate specific antigen |
| WO1999037811A1 (en) * | 1998-01-21 | 1999-07-29 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| JP2002516082A (ja) * | 1998-05-29 | 2002-06-04 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒト膜貫通タンパク質 |
-
2000
- 2000-10-06 CA CA002386669A patent/CA2386669A1/en not_active Abandoned
- 2000-10-06 AU AU78683/00A patent/AU7868300A/en not_active Abandoned
- 2000-10-06 JP JP2001528702A patent/JP2004500553A/ja active Pending
- 2000-10-06 WO PCT/US2000/027682 patent/WO2001025791A2/en not_active Ceased
- 2000-10-06 DE DE60032784T patent/DE60032784T2/de not_active Revoked
- 2000-10-06 EP EP00968823A patent/EP1224466B1/en not_active Revoked
- 2000-10-06 AT AT00968823T patent/ATE350662T1/de not_active IP Right Cessation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006038674A (ja) * | 2004-07-28 | 2006-02-09 | Kazuaki Kakehi | 糖たん白質糖鎖の分析方法及び非標識糖鎖の製造方法 |
| JP2008537112A (ja) * | 2005-04-07 | 2008-09-11 | モザイクヴェス ディアグノシュティクス アンド テラポイティクス アクチェン ゲゼルシャフト | 前立腺がんの診断のためのポリペプチドマーカー |
| JP2009530624A (ja) * | 2006-03-24 | 2009-08-27 | フェノメノーム ディスカバリーズ インク | 前立腺癌を診断するために有用なバイオマーカー及びその方法 |
| US8409794B2 (en) | 2006-03-24 | 2013-04-02 | Phenomenome Discoveries Inc. | Biomarkers useful for diagnosing prostate cancer, and methods thereof |
| JP2013092527A (ja) * | 2006-03-24 | 2013-05-16 | Phenomenome Discoveries Inc | 前立腺癌を診断するために有用なバイオマーカー及びその方法 |
| JP2013528379A (ja) * | 2010-05-21 | 2013-07-11 | オームクス コーポレーション | Ｐｓａ酵素活性アッセイによる癌の検出 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60032784T2 (de) | 2007-11-08 |
| AU7868300A (en) | 2001-05-10 |
| CA2386669A1 (en) | 2001-04-12 |
| WO2001025791A2 (en) | 2001-04-12 |
| EP1224466B1 (en) | 2007-01-03 |
| ATE350662T1 (de) | 2007-01-15 |
| WO2001025791A3 (en) | 2001-12-27 |
| DE60032784D1 (de) | 2007-02-15 |
| EP1224466A2 (en) | 2002-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1224466B1 (en) | Prostate cancer marker proteins | |
| AU2002243221B2 (en) | Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers | |
| US20100240088A1 (en) | Peptide Markers for Diagnosis of Angiogenesis | |
| EP1269194B1 (en) | Prostate cancer markers | |
| US20040018519A1 (en) | Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers | |
| US7297556B2 (en) | Method of diagnosing nephrotic syndrome | |
| US20090204334A1 (en) | Lung cancer biomarkers | |
| AU2002243221A1 (en) | Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers | |
| JP4801930B2 (ja) | 新規肝がんバイオマーカーおよび該バイオマーカーを用いた肝がんの検出方法 | |
| AU2001249275A1 (en) | Prostate cancer markers | |
| AU2017251859B2 (en) | SRM/MRM assay for subtyping lung histology | |
| US20100216654A1 (en) | Biomarkers of prostate cancer and uses thereof | |
| US20070087392A1 (en) | Method for diagnosing head and neck squamous cell carcinoma | |
| US20030228639A1 (en) | Prostate cancer markers | |
| WO2002023200A2 (en) | Human breast cancer biomarkers | |
| JP2004525343A (ja) | 膀胱の移行上皮癌の生物マーカー |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040520 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050816 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090108 |